Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Takeda Pharmaceutical Ord Shs TKPHF

Healthcare
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer)... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (OTCPK:TKPHF)

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

PR Newswire March 27, 2024

NICE Recommends Takhzyro® (Lanadelumab) for the Treatment of People Living With Rare Debilitating Genetic Disorder

PR Newswire September 18, 2019

Study shows investigational subcutaneous formulation of ENTYVIO® (vedolizumab) achieves and maintains clinical remission and mucosal healing in moderately to severely active ulcerative colitis

Canada NewsWire October 23, 2018

New Data Added to TRINTELLIX® (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder

PR Newswire October 22, 2018

New Real-World Data Analyses Support the Long-Term Use of Entyvio® (vedolizumab) in Bio-Naïve Patients for the Treatment of Moderate to Severe Ulcerative Colitis or Crohn's Disease

PR Newswire October 8, 2018

Analysis of real-world safety data shows gut-selective ENTYVIO® (vedolizumab) had fewer serious infections and adverse events than those on systemic TNFα-antagonist therapy in ulcerative colitis and Crohn's disease patients

Canada NewsWire June 5, 2018

Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

PR Newswire June 3, 2018

Takeda Activities at American Psychiatric Association (APA) Annual Meeting Innovation Zone Highlight Advancements in Mental Health

PR Newswire May 5, 2018

TRINTELLIX® (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)

PR Newswire May 2, 2018
View More News ››

Opinion & Analysis (OTCPK:TKPHF)

Four biotech mid-caps fund manager Eden Rahim believes have favorable catalysts

The Life Sciences Report April 6, 2017

Regenerative medicine in Japan: CJ PARTNERS' Colin Lee Novick ATHX, RP, RGS, 7774:TYO, 4527:TYO, 2372:TYO

Gail Dutton August 5, 2015
View More Opinion ››

Bullboard Posts (OTCPK:TKPHF)

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 C

Breaking News: $TAK Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA&#xAE; in Patients with...
whytestocks - June 18, 2024

Real stock price share value

4226$
Nibinator - November 14, 2023

colchicine vs covid

We got a new credible study out of Quebec. This drug is preventing: hospitalizations by 25%, the need for mechanical ventilation by 50%,...
GoldBrooke - January 25, 2021

Healthcare Stocks to Watch

There is a wide array of offerings from innovative care to advanced digital technologies from every corner of the market assessing just...
SHFeatureArticl - February 28, 2020
View more Bullboard ››

Promino Nutritional Sciences Inc.

Promino Nutritional Sciences Inc.

Promino Nutritional Sciences Inc., formerly Element Nutritional Sciences Inc., is a research-driven Canadian nutraceutical ...
View More »